Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies.

ABSTRACT: Breast cancer (BC) is the most commonly diagnosed cancer in women, constituting one-third of all cancers in women, and it is the second leading cause of cancer-related deaths in the United States. Anti-estrogen therapies, such as selective estrogen receptor modulators, significantly improve survival in estrogen receptor-positive (ER+) BC patients, which represents about 70% of cases. However, about 60% of patients inevitably experience intrinsic or acquired resistance to anti-estrogen therapies, representing a major clinical problem that leads to relapse, metastasis, and patient deaths. The resistance mechanisms involve mutations of the direct targets of anti-estrogen therapies, compensatory survival pathways, as well as alterations in the expression of non-coding RNAs (e.g., microRNA) tha

SUBMITTER: Ozyurt R 

PROVIDER: S-EPMC9655708 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature